Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ventyx Biosciences Inc (NQ: VTYX )

2.060 +0.210 (+11.35%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ventyx Biosciences Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
VENTYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ventyx Biosciences, Inc. on Behalf of Ventyx Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
The Latest Analyst Ratings for Ventyx Biosciences
Via Benzinga
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Ventyx Biosciences, Inc. (VTYX)
From Kirby McInerney LLP
Via Business Wire
Crude Oil Falls Sharply; Datadog Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 1% on Tuesday The Dow traded up 0.21% to 34,166.89 while the NASDAQ rose 1.09% to 13,666.65. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Shares of Ventyx Biosciences Are Dropping Tuesday
Investors were unimpressed by the company's trial results for an ulcerative colitis therapy. 
Via The Motley Fool
Where Ventyx Biosciences Stands With Analysts
Via Benzinga
Ventyx Crashes 81% After Scrapping Two Studies On A Psoriasis Treatment Flop
The company is now scrapping studies of its drug in psoriasis and psoriatic arthritis. 
Via Investor's Business Daily
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry. 
Via Benzinga
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Where Ventyx Biosciences Stands With Analysts
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Nasdaq Jumps 100 Points; US Trade Deficit Widens In September
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Tuesday The Dow traded up 0.19% to 34,159.14 while the NASDAQ rose 0.84% to 13,631.99. The... 
Via Benzinga
Topics Stocks
Exposures US Equities
US Stocks Mixed; D.R. Horton Earnings Top Views
U.S. stocks traded mixed this morning, with the Dow Jones falling around 50 points on Tuesday Following the market opening Tuesday, the Dow traded down 0.18% to 34,035.79 while the NASDAQ rose 0.14% to... 
Via Benzinga
Topics Stocks
Exposures US Equities
PTON Stock Slumps as Deutsche Bank Downgrades Peloton
Peloton stock is taking a beating on Tuesday after shares of PTON were downgraded and saw their price target reduced by Deutsche Bank. 
Via InvestorPlace
Why Is Psoriasis Player Ventyx Biosciences Stock Trading Lower Today?
Ventyx Biosciences Inc (NASDAQ: VTYX) released results from the Phase 2 trial of VTX958 in patients with moderate to  
Via Benzinga
Why Is Alto Ingredients (ALTO) Stock Down 45% Today?
Alto Ingredients stock is falling on Tuesday after the company released a mixed earnings report for the third quarter of the year. 
Via InvestorPlace
Why Is Ventyx Biosciences (VTYX) Stock Down 76% Today?
Ventyx Biosciences stock is taking a beating on Tuesday after the company announced it will end development of VTX958 on Phase 2 results. 
Via InvestorPlace
Why Alteryx Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares surged 120.8% to $0.6450 in pre-market trading after the company reported a new strategic collaboration with Celest Therapeutics for the clinical... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another dive into the biggest pre-market stock movers as we break down all of the latest news for Tuesday morning. 
Via InvestorPlace
Sanmina, Adtran, Ameresco And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Crude Oil Moves Lower; Neogen Posts Downbeat Results
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 175 points on Tuesday. The Dow traded up 0.53% to 33,781.59 while the NASDAQ rose 0.72% to 13,581.64. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday saw 132 companies set new 52-week lows. 
Via Benzinga
Why Startek Shares Are Trading Higher By 29%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers SuperCom Ltd. (NASDAQ: SPCB) shares jumped 89% to $0.6805, after falling 13% on Monday. 
Via Benzinga
S&P 500 Rises 1%; US Wholesale Inventories Fall In August
U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 250 points on Tuesday. The Dow traded up 0.81% to 33,876.62 while the NASDAQ rose 1.23% to 13,650.54. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures US Equities
PagerDuty, John Wiley & Sons, Ventyx Biosciences And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why Ventyx Biosciences Stock Fell After-Hours
Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares plunged in Monday's after-hours session after the company announced results from the Phase 2 trial of VTX002 in patients with moderate-to-severely 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS